BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Wyeth Research (New Jersey) (WYE) Named To R&D Directions Top 10 Pipeline List As 'The Strongest Primary-Care Pipeline'


2/15/2006 1:30:33 PM

MADISON, N.J., Feb. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today announced that the R&D Directions Annual Report of Top 10 Pharmaceutical Pipelines included the Wyeth pipeline as "The Strongest Primary-Care Pipeline." This is the second year in a row that Wyeth has been included in the list. In 2004, Wyeth was designated "The Pipeline to Watch."

Robert R. Ruffolo, Jr., Ph.D., President, Wyeth Research and Development (R&D) and Senior Vice President, Wyeth, accepted the honor on behalf of the company at an awards presentation yesterday at the Drug Discovery Summit in Phoenix, AZ, sponsored by R&D Directions.

In accepting the award Dr. Ruffolo noted, "Five years ago we set out to file two New Drug Applications (NDAs) per year for new molecular entities and now we have reached that goal. In the next 18 months we hope to be able to file as many as six NDAs."

A January 2006 profile of Wyeth's pipeline in the 10th Annual Report on the Top 10 Pipelines noted that Wyeth R&D has initiated several progressive measures to spur productivity, which has grown from an average 3.3 drugs per year placed into development to 12 drugs per year for the past five years. Wyeth R&D efforts are bolstered by the Company's ability to create medicines across three development platforms -- small molecules, proteins and vaccines - - an advantage that provides many scientific and commercial synergies and increases the opportunity to discover breakthrough treatments.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, hemophilia, oncology and vaccines.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

CONTACT: Media Contacts - Gerald Burr, Wyeth Pharmaceuticals,+1-484-865-5138; Investor Contact - Justin Victoria, Wyeth, +1-973-660-5340



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES